Home ›
Gastric Cancer Trials ›
NCT06371586
Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
Trial Details
NCT ID NCT06371586
Phase PHASE2
Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status RECRUITING
Cancer Type Gastric Cancer
Interventions Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Locations (sample) Beijing, China|39.9075,116.39723
Key Eligibility Criteria
Local advanced diffuse or mixed type gastric cancer detected by pathology and endoscopy; Chest, abdomen, and pelvis enhanced CT, neck and supraclavicular ultrasound, gastroscopy, and endoscopic ultrasound were used to diagnose T3-4NanyM… Has not received any anti-tumor treatment for gastric cancer yet; Age range from 18 to 75 years old;
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Gastric Cancer Trials on Trialify →